Introduction to Swiss HTA, P&R pathways and policies for medicines within the European perspective
|
|
This webinar will present the Swiss system for pricing and reimbursement of medicinal products, covering the process for inclusion in the Specialties List and alternative pathways. The speakers will also discuss market access for medicines from a European perspective and share insights into the latest policy and regulatory developments.
|
|
The webinar will cover the following points:
|
|
- European perspective on market access for medicinal products, including latest developments
- Pathways for pricing and reimbursement of medicines in Switzerland
- Impact of the revision of the Health Insurance Ordinance (KVV/OAMal)
|
|
Shayesteh Fürst-Ladani
Senior Vice-President, Head of SFL Group
Shayesteh has longstanding experience in providing comprehensive strategic advice for development of products including small molecules, biologics, drug & device combination products, medical devices, in vitro diagnostics (IVDs) and advanced therapy medicinal products (ATMPs). Before founding SFL, Shayesteh held senior level positions at various biotech and pharmaceutical companies. Shayesteh serves as President of the Board of Directors of the not-for-profit associations Rare Disease Action Forum (RDAF) and Medtech & Pharma Platform (MPP), and she lectures in Regulatory Affairs at the IFAPP Academy, Kings College London.
|
|
|
Anna Ulbricht
Senior Director Medical Affairs and Market Access
Anna provides strategic support on regular and exceptional access pathways to establish pricing and reimbursement of products in the EU and DACH regions, prepares payor and competitor landscape analyses, and develops value dossiers meeting national payor requirements and evidence needs. In-depth knowledge of Swiss payor perspectives has established Anna and her team as preferred partners to develop access strategies for Switzerland, prepare Swiss reimbursement applications (e.g. relating to inclusion of pharmaceuticals in the SL), and support early access solutions (e.g. reimbursement via Art. 71 a-d KVV), the FOPH’s triennial review of pharmaceuticals, as well as payor early dialogue and negotiations.
|
|
|
Nathalie Schober-Ladani
Senior Director Public Affairs and Regulatory Intelligence
Nathalie leads the Public Affairs and Regulatory Intelligence team at SFL and provides strategic policy and regulatory intelligence support to interdisciplinary projects for a wide range of products in the life sciences field. With a main interest in innovative product development and through regular interaction with stakeholders from academia, industry and patient groups, she has insights into different perspectives on current health policy and market access topics. Nathalie develops policy positions and conducts stakeholder analyses for SFL clients and plays a leading role in the engagement and organizational work of national and international associations such as the multi-stakeholder association on rare diseases in Switzerland, the Rare Disease Action Forum (RDAF).
|
|
|
SFL is a leading consultancy with a unique combination of expertise under one roof. Thanks to its experienced multidisciplinary team, SFL’s services cover the entire life cycle of healthcare products. SFL offers personalized and customized strategic advice and operational support of global as well as regional and national projects.
|
|
|
|
|
